Breaking News Instant updates and real-time market news.

AMAG

AMAG Pharmaceuticals

$23.29

-0.88 (-3.64%)

08:07
10/12/16
10/12
08:07
10/12/16
08:07

AMAG Pharmaceuticals achieves key milestones in Makena, Feraheme programs

AMAG Pharmaceuticals announced that it has achieved two key milestones in its next generation development programs. The definitive pharmacokinetic study and the comparative pain study for the Makena subcutaneous auto-injector program have been initiated with the first patient dosed. The enrollment of patients in the Feraheme Phase 3 label expansion trial for the treatment of iron deficiency anemia, or IDA, has surpassed approximately two-thirds of the total target enrollment of 2,000 patients, resulting in the acceleration of the estimated supplemental new drug application, or sNDA, filing date to mid-2017.

AMAG AMAG Pharmaceuticals
$23.29

-0.88 (-3.64%)

04/14/16
LEER
04/14/16
NO CHANGE
LEER
Partnership, acquisition activity to reemerge in biopharma, says Leerink
Leerink analyst Joseph Schwartz believes partnership and acquisition activity will reemerge as a key feature in the biopharma industry in the coming months based on pharma and large cap biotech's continued assertions that they are searching for new assets. The analyst's top ten list of future targets include ACADIA (ACAD), Akorn (AKRX), AMAG Pharmaceuticals (AMAG), Depomed (DEPO), Dermira (DERM), Intra-Cellular (ITCI), The Medicines Co. (MDCO), Retrophin (RTRX), Raptor Pharmaceutical (RPTP) and United Therapeutics (UTHR).
05/04/16
RAJA
05/04/16
DOWNGRADE
RAJA
Market Perform
AMAG downgraded to Market Perform from Outperform at Raymond James
Raymond James analyst Christopher Raymond downgraded AMAG Pharmaceuticals to Market Perform citing the Makena auto-injector delay. The analyst has "no comfort" that this delay will be the last.
05/17/16
LEER
05/17/16
NO CHANGE
Target $40
LEER
Outperform
ANI, Aspen deal only incremental negative for AMAG Pharma Makena, says Leerink
Leerink analyst Joseph Schwartz says ANI Pharmaceuticals (ANIP) announced an agreement with Aspen Global for Hydroxyprogesterone Caproate Injection, with Aspen responsible for supplying the finished goods and ANIP responsible for U.S. distribution. The analyst sees this deal as only an "incremental negative" for AMAG Pharmaceuticals' (AMAG) Makena sales in the second half of 2016. While Schwartz notes that the magnitude of this threat is still "poorly defined," he believes it will be less negative than if U.S. commercial rights had been out licensed to a major generic manufacturer with an existing commercial infrastructure in maternal health. Schwartz reiterates an Outperform rating and $40 price target on AMAG's shares.
09/01/16
LEER
09/01/16
NO CHANGE
Target $36
LEER
Outperform
AMAG Pharmaceuticals price target lowered to $36 from $40 at Leerink
Leerink analyst Joseph Schwartz lowered his price target for AMAG Pharmaceuticals (AMAG) to $36 from $40, saying he is wary that its Makena auto-injector will garner increased attention in 2018, similar to Mylan's (MYL) EpiPen. The analyst believes AMAG Pharmaceuticals' auto-injector will receive FDA approval but it remains to be seen whether approval timing and future potential achieve the company's expectations. He reiterates an Outperform rating on the AMAG Pharmaceuticals' shares.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.